ArticleMetabolic brain disease2020
Neuroprotective effects of Bacopa monnieri in Parkinson's disease model.
Article in Metabolic brain disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Multi-target mechanisms of Creatine in Parkinson's disease: an in-silico and in-vivo investigation.Genes & genomics · 2026Article
- Bacopaside-I ameliorates motor dysfunction and neurodegeneration in rat model of Parkinson's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A Comprehensive Review of Therapeutic Compounds from Plants for Neurodegenerative Diseases.Current medicinal chemistry · 2025Review
- Regulation of chronic neuroinflammation through dietary herbal products.Frontiers in nutrition · 2025Review
- Optimization of Parkinson's disease therapy with plant extracts and nutrition's evolving roles.IBRO neuroscience reports · 2024Review
- Investigating the Neuroprotective and Cognitive-Enhancing Effects ofAntioxidants (Basel, Switzerland) · 2024Review
- Gold Nanoparticles in Parkinson's Disease Therapy: A Focus on Plant-Based Green Synthesis.Cureus · 2024Review
- Genistein suppresses microglial activation and inhibits apoptosis in different brain regions of hypoxia-exposed mice model of amnesia.Metabolic brain disease · 2022Article
- Bacopa Protects against Neurotoxicity Induced by MPPMolecules (Basel, Switzerland) · 2022Article
- Pharmacological attributes ofFrontiers in nutrition · 2022Review
- Bacopaside-I Alleviates the Detrimental Effects of Acute Paraquat Intoxication in the Adult Zebrafish Brain.Neurochemical research · 2021Article
- Genistein Prevents Hypoxia-Induced Cognitive Dysfunctions by Ameliorating Oxidative Stress and Inflammation in the Hippocampus.Neurotoxicity research · 2021Article
- Neuroprotective and Neurorescue Mode of Action ofFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra region and the presence of α-synuclein aggregates in the striatum and surrounding areas of brain. Evidences suggest that neuroinflammation plays a role in the progression of PD. We examined the neuro-protective effects of Bacopa monnieri (BM) in regulating neuroinflammation. Administration of BM suppressed the level of pro-inflammatory cytokines, decreased the levels of α-synuclein, and reduced reactive oxygen species (ROS) generation in PD animal model. Pre-treatment of BM showed more prominent results as compare to co- and post-treatment. Results suggest that Bacopa can limit inflammation in the different areas of brain, thus, offers a promising source of novel therapeutics for the treatment of many CNS disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.